TrialNature medicine2024

Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.

Boris Julg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.